In the News
Medications for AUD appear beneficial in patients with cirrhosis
A systematic review and meta-analysis found that medications for alcohol use disorder (AUD) were associated with 32% more abstinence versus placebo or standard treatment in patients with alcohol-induced cirrhosis.
Phase 3 study offers evidence on drug dosing for eosinophilic esophagitis
Findings from an industry-funded study showed that using dupilumab weekly, rather than every two weeks, improved symptoms in adults and adolescents with eosinophilic esophagitis.
Prophylactic antibiotics help prevent post-ERCP infections
A randomized trial in Korea found that patients with biliary obstruction who underwent endoscopic retrograde cholangiopancreatography (ERCP) were less likely to develop infection if they received antibiotics before the procedure.
MKSAP Quiz: ICU admission for hematemesis
This month's quiz asks readers to determine the most appropriate next step in management for a 62-year-old man with cirrhosis and gastric varices.
Spotlight on cancer and GERD
One study found low risk of esophageal adenocarcinoma in patients with nonerosive gastroesophageal reflux disease (GERD), while another showed that antireflux surgery did not appear to decrease cancer risk among patients with Barrett's esophagus.
Studies show mixed results for artificial intelligence during colonoscopies
One study found a higher adenoma detection rate in patients who underwent computer-aided detection compared to standard colonoscopy, while another found that artificial intelligence did not improve identification of advanced colorectal neoplasias.
Patients with discordant C. difficile test results had lower mortality with treatment
Patients who were positive for Clostridioides difficile on nucleic acid amplification testing but negative on toxin immunoassay had similar 30-day mortality to those with positive results on both tests, according to a review of observational studies.
Case report published on hyperlipasemia due to duodenal obstruction
A 30-year-old nonverbal woman who had cerebral palsy and a chronic gastrostomy tube presented with nonbilious vomiting of tube feeds and abdominal pain.
In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk
The benefits of upadacitinib need to be weighed against individual patients' risk profiles, but the drug is an important step forward in treating Crohn disease, an ACP Journal Club commentary said.